These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 10860928)

  • 1. Acetyl-boswellic acids are novel catalytic inhibitors of human topoisomerases I and IIalpha.
    Syrovets T; Büchele B; Gedig E; Slupsky JR; Simmet T
    Mol Pharmacol; 2000 Jul; 58(1):71-81. PubMed ID: 10860928
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological evaluation of a halogenated triterpenoid, 2α-bromo-dihydrobelulonic acid as inhibitor of human topoisomerase IIα and HeLa cell proliferation.
    Ghosh S; Mukhopadhyay S; Sarkar M; Mandal A; Das V; Kumar A; Giri B
    Chem Biol Interact; 2017 Apr; 268():68-76. PubMed ID: 28254521
    [TBL] [Abstract][Full Text] [Related]  

  • 3. DNA topoisomerases as targets for the anticancer drug TAS-103: DNA interactions and topoisomerase catalytic inhibition.
    Fortune JM; Velea L; Graves DE; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15580-6. PubMed ID: 10569942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acetyl-11-keto-beta-boswellic acid induces apoptosis in HL-60 and CCRF-CEM cells and inhibits topoisomerase I.
    Hoernlein RF; Orlikowsky T; Zehrer C; Niethammer D; Sailer ER; Simmet T; Dannecker GE; Ammon HP
    J Pharmacol Exp Ther; 1999 Feb; 288(2):613-9. PubMed ID: 9918566
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II.
    Kruczynski A; Barret JM; Van Hille B; Chansard N; Astruc J; Menon Y; Duchier C; Créancier L; Hill BT
    Clin Cancer Res; 2004 May; 10(9):3156-68. PubMed ID: 15131057
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transfection of 9-hydroxyellipticine-resistant Chinese hamster fibroblasts with human topoisomerase IIalpha cDNA: selective restoration of the sensitivity to DNA religation inhibitors.
    Khélifa T; René B; Le Mée S; Lambert B; Saucier JM; Markovits J; Jacquemin-Sablon H; Jacquemin-Sablon A
    Cancer Res; 1999 Oct; 59(19):4927-36. PubMed ID: 10519406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. DNA topoisomerases as targets for the anticancer drug TAS-103: primary cellular target and DNA cleavage enhancement.
    Byl JA; Fortune JM; Burden DA; Nitiss JL; Utsugi T; Yamada Y; Osheroff N
    Biochemistry; 1999 Nov; 38(47):15573-9. PubMed ID: 10569941
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of topoisomerases by fatty acids.
    Suzuki K; Shono F; Kai H; Uno T; Uyeda M
    J Enzyme Inhib; 2000; 15(4):357-66. PubMed ID: 10995067
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synthesis and biological evaluation of C1-O-substituted-3-(3-butylamino-2-hydroxy-propoxy)-xanthen-9-one as topoisomerase IIα catalytic inhibitors.
    Park S; Hong E; Kwak SY; Jun KY; Lee ES; Kwon Y; Na Y
    Eur J Med Chem; 2016 Nov; 123():211-225. PubMed ID: 27484510
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The p53 tumor suppressor stimulates the catalytic activity of human topoisomerase IIalpha by enhancing the rate of ATP hydrolysis.
    Kwon Y; Shin BS; Chung IK
    J Biol Chem; 2000 Jun; 275(24):18503-10. PubMed ID: 10764786
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Catalytic inhibition of human DNA topoisomerase IIalpha by hypericin, a naphthodianthrone from St. John's wort (Hypericum perforatum).
    Peebles KA; Baker RK; Kurz EU; Schneider BJ; Kroll DJ
    Biochem Pharmacol; 2001 Oct; 62(8):1059-70. PubMed ID: 11597574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, topoisomerase I & II inhibitory activity, antiproliferative activity, and structure-activity relationship study of pyrazoline derivatives: An ATP-competitive human topoisomerase IIα catalytic inhibitor.
    Ahmad P; Woo H; Jun KY; Kadi AA; Abdel-Aziz HA; Kwon Y; Rahman AF
    Bioorg Med Chem; 2016 Apr; 24(8):1898-908. PubMed ID: 26988802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.
    Patel S; Jazrawi E; Creighton AM; Austin CA; Fisher LM
    Mol Pharmacol; 2000 Sep; 58(3):560-8. PubMed ID: 10953049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HU-331 is a catalytic inhibitor of topoisomerase IIα.
    Regal KM; Mercer SL; Deweese JE
    Chem Res Toxicol; 2014 Dec; 27(12):2044-51. PubMed ID: 25409338
    [TBL] [Abstract][Full Text] [Related]  

  • 16. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action.
    Perrin D; van Hille B; Barret JM; Kruczynski A; Etiévant C; Imbert T; Hill BT
    Biochem Pharmacol; 2000 Apr; 59(7):807-19. PubMed ID: 10718339
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cell cycle-coupled relocation of types I and II topoisomerases and modulation of catalytic enzyme activities.
    Meyer KN; Kjeldsen E; Straub T; Knudsen BR; Hickson ID; Kikuchi A; Kreipe H; Boege F
    J Cell Biol; 1997 Feb; 136(4):775-88. PubMed ID: 9049244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel xanthone-polyamine conjugates as catalytic inhibitors of human topoisomerase IIα.
    Minniti E; Byl JAW; Riccardi L; Sissi C; Rosini M; De Vivo M; Minarini A; Osheroff N
    Bioorg Med Chem Lett; 2017 Oct; 27(20):4687-4693. PubMed ID: 28919339
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential in vitro interactions of a series of clinically useful topoisomerase-interacting compounds with the cleavage/religation activity of the human topoisomerase IIalpha and IIbeta isoforms.
    van Hille B; Perrin D; Hill BT
    Anticancer Drugs; 1999 Jul; 10(6):551-60. PubMed ID: 10885903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Substrate specificity plays an important role in uncoupling the catalytic and scaffolding activities of rat testis DNA topoisomerase IIalpha.
    Bakshi R; Galande S; Muniyappa K
    J Biomol Struct Dyn; 2001 Apr; 18(5):749-60. PubMed ID: 11334111
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.